Mesoblast Limited (NASDAQ:MESO) Receives $13.67 Consensus Price Target from Analysts

Shares of Mesoblast Limited (NASDAQ:MESO) have been assigned a consensus rating of “Hold” from the six analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $13.67.

MESO has been the subject of a number of analyst reports. StockNews.com lowered Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a report on Friday, January 12th.

Mesoblast Stock Down 5.5 %

Shares of Mesoblast stock opened at $7.17 on Tuesday. The company has a market cap of $818.66 million, a PE ratio of -6.40 and a beta of 3.45. Mesoblast has a 52 week low of $1.61 and a 52 week high of $10.24. The business has a 50 day moving average price of $4.75 and a 200-day moving average price of $3.05.

Institutional Trading of Mesoblast

A number of institutional investors have recently modified their holdings of the business. Prosperity Wealth Management Inc. purchased a new position in Mesoblast in the 3rd quarter valued at approximately $79,000. Lazari Capital Management Inc. grew its position in shares of Mesoblast by 9.3% in the third quarter. Lazari Capital Management Inc. now owns 94,034 shares of the company’s stock valued at $116,000 after purchasing an additional 8,000 shares in the last quarter. Finally, Chase Investment Counsel Corp bought a new stake in shares of Mesoblast during the 1st quarter valued at $298,000. 1.43% of the stock is currently owned by hedge funds and other institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.